Key Equity Research Analysts at Barclays Didn’t Change their ‘”Overweight”’ rating for Shire (LON:SHP) Shares Today. Their Target Price Provided Is GBX 5700


Shire (LON:SHP) Rating Reaffirmed

Barclays now has a GBX 5700 PT on shares of Shire (LON:SHP). The PT may suggest a potential upside of 28.64% from the current price of Shire (LON:SHP). This rating was shown in a note on Thursday morning.

From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.97. The mean of all analyst targets is GBX 89.82 with a 21.23% above today’s (GBX 4444) stock price. Shire PLC was the topic of 85 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Barclays Capital maintained shares on December 15 with “Overweight” rating. Berenberg maintained shares with “Buy” rating and GBX 6300 target share price in a report from a November 16. BNP Paribas maintained SHP stock in a recent report from December 9 with “Neutral” rating. Credit Suisse maintained the rating on November 4. Credit Suisse has a “Neutral” rating and a GBX 5400 price target on shares. Finally, JP Morgan maintained the stock with “Overweight” rating in a report issued on a December 4.

Approximately 312,734 shares of stock traded hands. Shire PLC (LON:SHP) has declined 20.60% since May 20, 2015 and is downtrending. It has underperformed by 18.34% the S&P500.

Key Equity Research Analysts at Barclays Didn't Change their ‘

Shire plc is a biopharmaceutical company. The company has a market cap of 25.54 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 12.98 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.